In May 2026, European markets have shown resilience with the pan-European STOXX Europe 600 Index rising by 3.00%, driven by optimism surrounding potential de-escalation in the Middle East. Despite a reduction in growth forecasts due to energy shocks and geopolitical challenges, investor interest remains strong for growth companies where high insider ownership can signal confidence and alignment with shareholder interests.
Top 10 Growth Companies With High Insider Ownership In Europe
|
Name |
Insider Ownership |
Earnings Growth |
|
XTPL (WSE:XTP) |
23.3% |
83% |
|
KebNi (OM:KEBNI B) |
11.8% |
82.7% |
|
Hacksaw (OM:HACK) |
13.2% |
24.8% |
|
Envipco Holding (ENXTAM:ENVI) |
19.5% |
91.1% |
|
CTT Systems (OM:CTT) |
17.4% |
47.1% |
|
Clavister Holding AB (publ.) (OM:CLAV) |
18% |
83.1% |
|
Circus (XTRA:CA1) |
21.9% |
84.3% |
|
Bonesupport Holding (OM:BONEX) |
10.6% |
33.8% |
|
BioArctic (OM:BIOA B) |
32.2% |
53.3% |
|
Bergen Carbon Solutions (OB:BCS) |
11.9% |
50.2% |
Let’s uncover some gems from our specialized screener.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Ambu A/S is a company that researches, develops, manufactures, markets, and sells medical technology solutions globally, with a market cap of DKK18.04 billion.
Operations: The company’s revenue is derived from its Medical Technology Solutions segment, which generated DKK6.10 billion.
Insider Ownership: 20.3%
Ambu demonstrates strong growth potential with forecasted earnings growth of 23.6% annually, outpacing the Danish market’s 9.2%. Despite a decline in recent quarterly net income to DKK 121 million, insider confidence remains stable with no substantial selling and modest buying over the past three months. While trading below estimated fair value by 48.1%, Ambu’s revenue is expected to grow faster than the market at 10.7% per year, supporting its position as a promising growth entity in Europe.
Simply Wall St Growth Rating: ★★★★★★
Overview: Bonesupport Holding AB is an orthobiologics company that develops and commercializes injectable bio-ceramic bone graft substitutes across the United States, Europe, and internationally, with a market cap of SEK17.33 billion.
Operations: Bonesupport Holding AB generates revenue primarily from its Pharmaceuticals segment, which amounted to SEK1.22 billion.
Insider Ownership: 10.6%
Bonesupport Holding is poised for significant growth, with earnings expected to rise by 33.8% annually, surpassing the Swedish market’s 8.7%. Recent quarterly results showed a substantial increase in net income to SEK 53.38 million from SEK 10.43 million the previous year. Insider activity indicates more shares bought than sold recently, and analysts project a potential stock price increase of 42%. The company trades at a notable discount of 39.6% below its fair value estimate.

